Our Blog

With Cancer, There is No Waiting Game
Guest User Guest User

With Cancer, There is No Waiting Game

The best prostate cancer outcomes begin with better answers. Get yours with Myriad Genetic testing.

If you’re newly diagnosed with prostate cancer or have already been treated for it, there are simple genetic tests that offer peace of mind and greater hope. Myriad genetic testing shows if you inherited a mutation that may have caused your cancer and whether your family members have an elevated risk. And if you’ve previously been treated for prostate cancer, genetic testing can identify your risk of

developing secondary cancer in the future.

Read More
U.S. FDA Approves Additional Indication of NUBEQA®
Guest User Guest User

U.S. FDA Approves Additional Indication of NUBEQA®

WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).1

The approval is based on results of the Phase III ARASENS trial that demonstrated a statistically significant increase in

Read More
Aviator Cancer Bill Would Push VA to Study Toxins Air Crews Faced, Assess Links to Cancers
Guest User Guest User

Aviator Cancer Bill Would Push VA to Study Toxins Air Crews Faced, Assess Links to Cancers

Just like the fighter pilots they supported, many troops who fueled, armed, and maintained warplanes have suffered from cancer or seen their former colleagues diagnosed with the disease. There’s no data yet on how many ground crew members have gotten sick, but a new bill introduced Thursday would require the Department of Veterans Affairs to identify the cancer incidence in the entire aviation community, as well as what toxins they faced, and whether there could be a link to their illnesses.

Read More